BioPorto A/S (THOXF)
OTCMKTS · Delayed Price · Currency is USD
0.2880
+0.0580 (25.22%)
At close: Jun 26, 2024

BioPorto Company Description

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally.

It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease.

The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays.

BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.

BioPorto A/S
BioPorto logo
CountryDenmark
Founded1917
IndustryDiagnostics & Research
SectorHealthcare
Employees48
CEOPeter Eriksen

Contact Details

Address:
Tuborg Havnevej 15, st.
Hellerup, 2900
Denmark
Phone45 45 29 00 00
Websitebioporto.com

Stock Details

Ticker SymbolTHOXF
ExchangeOTCMKTS
Stock TypeCommon Stock
Share ClassClass B Shares
Fiscal YearJanuary - December
Reporting CurrencyDKK
ISIN NumberDK0011048619
SIC Code2836

Key Executives

NamePosition
Jeffrey N. HaasPresident and Chief Executive Officer of BioPorto Inc.
Peter Moerch Eriksen B.B.A., BBAChief Executive Officer
Niels Hoey NielsenExecutive Vice President and Group Chief Financial Officer
Gry Husby LarsenExecutive Vice President and Group Chief Legal Officer
Hanne SogaardHead of Investor Relations
Jennifer ZondermanSenior Vice President of Global Marketing and Commercialization
Ursula Klause Ph.D.Senior Vice President of Global Clinical and Technical Development